PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 16, 2026Degenerative Neurological and Neuromuscular DiseaseOpen Access

Effectiveness of Siponimod with Up to 2 Years of Treatment in a Real-World Setting in People with SPMS: Analysis from the Novartis Global Managed Access Program

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAntonio CarotenutoDNDimitris NaoumisVMVincenzo Brescia Morra

Discussion

Loading...

Member takes

Overview

Analysis of real-world data shows siponimod's effectiveness in secondary progressive multiple sclerosis, suggesting potential benefits for patients.

Key Points

  • To analyze the effectiveness of siponimod in patients with secondary progressive multiple sclerosis under a managed access program.
  • Data collected from physicians in countries where siponimod was not yet approved.
  • Patient demographic and clinical characteristics analyzed between February 2019 and April 2022.
  • Utilized a Novartis database for information on clinical outcomes.
  • Mean EDSS at baseline among 516 patients was 5.2.
  • Post-baseline data showed a change in EDSS score of −0.04 at month 6 and 0.03 at month 24.
  • Annual relapse rate was 0.023.
  • 93.3% of patients assessed with MRI had no signs of disease activity.

Cite This Study

Carotenuto et al. (2026) studied this question.

synapsesocial.com/papers/69e07dfe2f7e8953b7cbef79https://doi.org/10.2147/dnnd.s540207
View Full Paper
Ask AI
Bookmark
Share